+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase II Study of Irinotecan and Capecitabine Concurrent With Intensity Modulated Radiation Therapy in the Treatment of Recurrent Rectal Cancer



Phase II Study of Irinotecan and Capecitabine Concurrent With Intensity Modulated Radiation Therapy in the Treatment of Recurrent Rectal Cancer



International Journal of Radiation Oncology*biology*physics 84(3): S194-S195




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 064229438

Download citation: RISBibTeXText

DOI: 10.1016/j.ijrobp.2012.07.504


Related references

CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer. Radiation Oncology 10(): 57-57, 2016

Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. International Journal of Radiation Oncology, Biology, Physics 91(1): 116-123, 2015

RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer. Journal of Clinical Oncology 26(15_suppl): 4021-4021, 2016

Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. International Journal of Radiation Oncology, Biology, Physics 82(4): 1367-1375, 2012

Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. International Journal of Radiation Oncology, Biology, Physics 83(2): 587-593, 2012

NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology, Biology, Physics 93(1): 29-36, 2015

Phase I study of radiotherapy (RT) plus concurrent irinotecan (CPT-11) and capecitabine (CAP) as preoperative downstaging treatment for locally advanced inoperable rectal cancer. Journal of Clinical Oncology 23(16_suppl): 3565-3565, 2016

Radiotherapy plus concurrent irinotecan (CPT-11) and capecitabine (CAP) as preoperative downstaging treatment for locally advanced inoperable rectal cancer: A phase I/II study. Journal of Clinical Oncology 24(18_suppl): 13519-13519, 2016

A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. American Journal of Clinical Oncology 33(3): 242-245, 2010

Phase I trial of preoperative hypofractionated intensity modulated radiation therapy (IMRT) with incorporated boost and oral capecitabine in locally advanced rectal cancer (vol 67, pg 651, 2007). International Journal of Radiation Oncology Biology Physics 69(1): 320, 2007

Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer. International Journal of Radiation Oncology, Biology, Physics 71(3): 748-755, 2008

Phase I study of capecitabine, carboplatin and intensity-modulated radiation therapy for head and neck cancer. Anticancer Research 29(7): 2869-2873, 2009

Phase II trial of capecitabine and irinotecan in combination with concurrent radiotherapy for neoadjuvant treatment of locally advanced rectal cancer. Journal of Clinical Oncology 23(16_suppl): 3589-3589, 2016

Preliminary results of a phase II neoadjuvant trial with gemcitabine/oxaliplatin and cetuximab followed by surgery or concurrent intensity modulated radiation therapy (IMRT) with capecitabine for patients with borderline resectable and unresectable nonmetastatic pancreatic cancer. Journal of Clinical Oncology 26(15_suppl): 15506-15506, 2016

Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. Cancer 115(21): 5117-5125, 2009